GAPLINC

Summary

GAPLINC (gastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA, HGNC:51308) is a long non-coding RNA gene on chromosome 18p11.31.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:51308
Approved symbol	GAPLINC
Name	gastric adenocarcinoma associated, positive CD44 regulator, long intergenic non-coding RNA
Location	18p11.31
Locus type	RNA, long non-coding
Status	Approved
Aliases	TCONS_00026238, lncRNA-uc002kmd.1, RP11-838N2.4
Ensembl gene	ENSG00000266835
Ensembl biotype	lncRNA
Entrez	100505592
RNAcentral	URS000075DC77 — lncRNA, 511 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 14 — 14 lncRNA

ENST00000578664, ENST00000579007, ENST00000581029, ENST00000581442, ENST00000700774, ENST00000790303, ENST00000790304, ENST00000790305, ENST00000790306, ENST00000790307, ENST00000790308, ENST00000790309, ENST00000790310, ENST00000790311

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000578664 — 4 exons

Exon	Start	End
ENSE00002694995	3473954	3474142
ENSE00002725208	3467127	3467270
ENSE00003864336	3466291	3466357
ENSE00004170427	3478756	3478978

Expression profiles

Bgee: expression breadth ubiquitous, 153 present calls, max score 81.02.

FANTOM5 (CAGE): breadth broad, TPM avg 3.1349 / max 123.9731, expressed in 548 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
169198	3.1349	548

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	81.02	gold quality
sural nerve	UBERON:0015488	80.59	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	80.37	gold quality
prostate gland	UBERON:0002367	74.63	gold quality
stromal cell of endometrium	CL:0002255	69.67	gold quality
calcaneal tendon	UBERON:0003701	69.01	gold quality
tendon of biceps brachii	UBERON:0008188	67.82	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	66.41	gold quality
upper lobe of left lung	UBERON:0008952	66.34	gold quality
tendon	UBERON:0000043	66.26	gold quality
placenta	UBERON:0001987	66.07	gold quality
gall bladder	UBERON:0002110	65.67	gold quality
upper lobe of lung	UBERON:0008948	65.43	gold quality
rectum	UBERON:0001052	65.34	gold quality
right lung	UBERON:0002167	65.03	gold quality
amniotic fluid	UBERON:0000173	64.48	silver quality
myocardium	UBERON:0002349	64.33	gold quality
buccal mucosa cell	CL:0002336	63.69	gold quality
mucosa of stomach	UBERON:0001199	62.85	gold quality
left coronary artery	UBERON:0001626	61.90	gold quality
popliteal artery	UBERON:0002250	61.42	gold quality
tibial artery	UBERON:0007610	61.41	gold quality
islet of Langerhans	UBERON:0000006	61.27	gold quality
ganglionic eminence	UBERON:0004023	61.24	gold quality
lung	UBERON:0002048	60.83	gold quality
descending thoracic aorta	UBERON:0002345	60.82	gold quality
aorta	UBERON:0000947	60.81	gold quality
coronary artery	UBERON:0001621	60.50	gold quality
right coronary artery	UBERON:0001625	60.45	gold quality
omental fat pad	UBERON:0010414	60.38	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.71

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 10)

• GAPLINC has a role in promoting colorectal cancer invasion via binding to PSF/NONO and partly by stimulating the expression of SNAI2 (PMID:27259250)
• The in vitro studies showed knockdown of GAPLINC depressed osteosarcoma cell migration and invasion via inhibiting CD44 expression, but no effect on cell proliferation. In conclusion, GAPLINC may serve as a potential biomarker for predicting prognosis and developing therapy for osteosarcoma. (PMID:30177521)
• GAPLINC promotes Non-Small Cell Lung Cancer tumorigenesis by regulating miR-661/eEF2K cascade. (PMID:30522114)
• GAPLINC expression was significantly upregulated in both glioblastoma (GBM) tissues and cell lines. The overexpression of GAPLINC was associated with shorter overall and disease-free survival. GAPLINC silencing suppressed GBM cells proliferation, migration, and invasion, and promoted apoptosis. GAPLINC acted as a competing endogenous RNA to sponge miR-331-3p and knockdown of GAPLINC promoted the expression of miR-331-3p. (PMID:30657584)
• Our results suggest that elevated GAPLINC was associated with poor clinical outcomes and might serve as a promising prognostic biomarker in cancer survivors (PMID:30904361)
• Poor expression of long-chain noncoding RNA GAPLINC inhibits epithelial-mesenchymal transition, and invasion and migration of hepatocellular carcinoma cells. (PMID:31415284)
• Long non-coding RNA GAPLINC promotes angiogenesis by regulating miR-211 under hypoxia in human umbilical vein endothelial cells. (PMID:31589383)
• A conserved long noncoding RNA, GAPLINC, modulates the immune response during endotoxic shock. (PMID:33568531)
• Serum Levels of Long Non-coding RNAs NEAT1, GAS5, and GAPLINC Altered in Rheumatoid Arthritis. (PMID:37855286)
• Macrophage-enriched novel functional long noncoding RNAs LRRC75A-AS1 and GAPLINC regulate polarization and innate immune responses. (PMID:38592458)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.